Agios Pharmaceuticals (AGIO) closed the last trading session at $32.80, gaining 10.4% over the past four weeks, but there ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had a good week, as its shares rose 9.7% to close at US$34.54 ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago.

In a nutshell, Agios Pharmaceuticals Inc (AGIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that ...

Agios Pharmaceuticals AGIO reported a loss of $1.45 per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $1.64. In the year-ago quarter, the company reported a loss ...

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat ...